# A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)

> **NCT00435669** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 4 (actual)

## Conditions studied

- Tumors

## Interventions

- **DRUG:** Brivanib
- **DRUG:** Brivanib

## Key facts

- **NCT ID:** NCT00435669
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2009-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00435669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00435669, "A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00435669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*